Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA clearance to add three new targets to its xTAG® Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. In addition, FDA has now cleared xTAG GPP for use with specimens in Cary-Blair medium, a common transport medium for collection and preservation of microbiological specimens.

"xTAG GPP helps me quickly identify the causes of gastroenteritis by testing for viruses, bacteria and parasites in one test," said Dr. Anami Patel, Director at Le Bonheur Children's Hospital. "Additionally, I have the flexibility to tailor the xTAG GPP test to physician orders which is useful for customizing the panel to different patient populations. Because I can process many samples at one time with the scalable format of xTAG GPP, I can be more efficient in my laboratory testing meeting increased demand when necessary which is especially important in outbreak situations."

As the first multiplexed U.S. IVD cleared test for infectious gastroenteritis, xTAG GPP simultaneously detects 14 common viral, bacterial, and parasitic causative pathogens from a single patient sample. By testing for greater than 90% of the causative pathogens of infectious gastroenteritis in a single test, clinicians can more quickly identify and treat the causative agent. Additionally co-infections can be more easily identified.

Simultaneous molecular testing on a single sample within a single shift also provides significant benefits to laboratories in terms of workflow and resource utilization. The ability to scale throughput by processing 96-well plates allows laboratories to easily tailor their sample processing to physician demand.

"We are dedicated to our customers and strive to continually update and improve our products to advance the delivery of health care," said Patrick J. Balthrop, president and chief executive officer of Luminex. "We are pleased to receive clearance for this new specimen medium and these additional clinical targets which provide even more flexibility to our customers. As laboratories are being asked to do more with less, we are continually working to deliver solutions that meet the varied needs of our customers."

Luminex will be featuring xTAG GPP at Infectious Disease Week, IDSA Annual Meeting, October 8–12 in Philadelphia, PA, Booth #522.

Source:

Luminex Corporation

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Luminex. (2019, June 20). Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel. News-Medical. Retrieved on November 30, 2020 from https://www.news-medical.net/news/20140930/Luminex-gets-FDA-approval-to-add-three-new-targets-to-xTAG-Gastrointestinal-Pathogen-Panel.aspx.

  • MLA

    Luminex. "Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel". News-Medical. 30 November 2020. <https://www.news-medical.net/news/20140930/Luminex-gets-FDA-approval-to-add-three-new-targets-to-xTAG-Gastrointestinal-Pathogen-Panel.aspx>.

  • Chicago

    Luminex. "Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel". News-Medical. https://www.news-medical.net/news/20140930/Luminex-gets-FDA-approval-to-add-three-new-targets-to-xTAG-Gastrointestinal-Pathogen-Panel.aspx. (accessed November 30, 2020).

  • Harvard

    Luminex. 2019. Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel. News-Medical, viewed 30 November 2020, https://www.news-medical.net/news/20140930/Luminex-gets-FDA-approval-to-add-three-new-targets-to-xTAG-Gastrointestinal-Pathogen-Panel.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Luminex announces group B strep as fifth assay planned for launch menu of ARIES